Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD) - Full Text View

Sponsors and Collaborators:	Massachusetts General Hospital Forest Laboratories
Information provided by:	Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00116532

Purpose

The purpose of this study is to assess the efficacy of Escitalopram in the treatment of obsessive compulsive disorder and to determine the optimal treatment dose.

Condition	Intervention	Phase
Obsessive Compulsive Disorder	Drug: Escitalopram	Phase IV

MedlinePlus related topics: Obsessive-Compulsive Disorder

Drug Information available for: Benzetimide Dexetimide Citalopram hydrobromide Citalopram Escitalopram Escitalopram oxalate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Efficacy Study
Official Title:	Escitalopram for the Treatment of Obsessive Compulsive Disorder

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:

Y-BOCs scores at 1st and last visit (16 weeks later)
Clinical Global impressions Scale at 2nd visit (2 weeks after 1st visit) and 6th visit (16 weeks post 1st visit)

Secondary Outcome Measures:

HAMD - first and last visit (Given week 0, 2, 4, 8, 12, & 16. Comparisons from week 0 and 16)
BDI - first and last visit (Given week 0, 2, 4, 8, 12, & 16. Comparisons from week 0 and 16)
BAI - first and last visit Given week 0, 2, 4, 8, 12, & 16. Comparisons from week 0 and 16)
QLESQ - first and last visit (week 0 and 16)

Estimated Enrollment:	30
Study Start Date:	October 2002
Study Completion Date:	February 2007

Detailed Description:

Background and Purpose: Obsessive compulsive disorder affects approximately 3% of the population. Treatment options include the selective serotonin reuptake inhibitors (SSRIs), dual serotonin and norepinephrine reuptake inhibitors, and behavioral therapy. A recent double-blind, placebo-controlled trial demonstrated that citalopram is effective in the treatment of OCD. Escitalopram is a new SSRI that may be more effective than other SSRIs for the treatment of major depression and may have fewer side effects. This study aims to assess the efficacy of escitalopram for the treatment of OCD.

Comparisons: Subject Y-BOCs pre-post treatment. We will also compare the improvement of subjects across the three different medication levels: 10 mg, 20 mg, and 30 mg.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of OCD by DSM-IV
Age 18-65
Y-BOCS greater than 20
Written informed consent
Females of childbearing potential must have a negative serum or urinary beta-HCG test.

Exclusion Criteria:

Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception.
Patients who, in the investigator’s judgement, pose a serious suicidal or homicidal risk.
Serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease. Patients on anticoagulant therapy.
History of seizure disorder
Comorbid bipolar disorder, psychosis, organic mental disorder, or developmental disorder
If there is a history of substance abuse, patients in remission at least 6 months.
Currently being treated with behavioral therapy, specifically exposure and response prevention, for OCD.
Other medications for medical disorders that may interfere with escitalopram
Current major depression or prescribed an antidepressant for major depression within the past 12 months.
Taken an SSRI medication within 2 weeks of beginning the study (4 weeks for fluoxetine).
More than 1 adequate trial (at least 10 weeks at maximally tolerated dose) with another SSRI in the past.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00116532

Locations

United States, Massachusetts
Massachusetts General Hospital - OCD Clinic
Charlestown, Massachusetts, United States, 02129

Sponsors and Collaborators

Massachusetts General Hospital

Forest Laboratories

Investigators

Principal Investigator:

Darin D Dougherty, MD

Massachusetts General Hospital

More Information

No publications provided

Study ID Numbers:	2002-P-000895, LXP-MD-14, 1200-211220
Study First Received:	June 29, 2005
Last Updated:	April 23, 2007
ClinicalTrials.gov Identifier:	NCT00116532 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:

Obsessive Compulsive Disorder
Escitalopram
SSRI
Open Label

Study placed in the following topic categories:

Neurotransmitter Agents
Cholinergic Antagonists
Psychotropic Drugs
Cholinergic Agents
Citalopram
Serotonin Uptake Inhibitors
Serotonin
Muscarinic Antagonists

Anxiety Disorders
Mental Disorders
Peripheral Nervous System Agents
Dexetimide
Antidepressive Agents, Second-Generation
Obsessive-Compulsive Disorder
Antidepressive Agents

Additional relevant MeSH terms:

Parasympatholytics
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Psychotropic Drugs
Antiparkinson Agents
Cholinergic Agents
Pathologic Processes
Mental Disorders
Therapeutic Uses
Dexetimide

Antidepressive Agents, Second-Generation
Obsessive-Compulsive Disorder
Antidepressive Agents
Disease
Citalopram
Serotonin Uptake Inhibitors
Pharmacologic Actions
Muscarinic Antagonists
Serotonin Agents
Anxiety Disorders
Autonomic Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 07, 2009